The failed skin cancer trial that crushed Incyte and Merck on Friday could be cause for alarm over at Bristol-Myers Squibb, which is running a nearly identical study with two drugs of its own that work the same way.

Like Incyte (INCY) and Merck (MRK), Bristol-Myers (BMY) is testing a two-drug combination that pairs a blockbuster immunotherapy with an unapproved pill that might make the older drug more effective. For Bristol-Myers, that pill is called BMS-986205, and it works by targeting an enzyme called IDO, which plays a role in helping tumors evade the immune system’s detection.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy